Summary
Boston Scientific Corporation (BSX) has received a Notice of Deficiency from the IRS regarding an audit of Guidant Corporation's tax years 2004-2006. The IRS claims an additional net tax liability of $581 million, plus interest and penalties. This notice is consistent with a prior Revenue Agent's Report and primarily concerns intercompany transfer pricing related to technology licenses and the 2006 sale of Guidant's vascular intervention business to Abbott Laboratories. The company strongly disagrees with the IRS's position, particularly regarding the assessment of third-party agreements, and intends to contest the notice in U.S. Tax Court. While BSX believes it has strong defenses and that its existing tax reserves are adequate, it acknowledges that the resolution of this matter is uncertain and could materially impact its financial condition or results of operations, potentially taking several years to resolve. No immediate payment is required pending resolution.
Key Highlights
- 1IRS Notice of Deficiency received for $581 million in additional net taxes plus interest and penalties for Guidant's 2004-2006 tax years.
- 2Dispute primarily relates to intercompany transfer pricing and the 2006 sale of Guidant's vascular intervention business to Abbott.
- 3Boston Scientific disputes the IRS's methodologies and assessment, asserting the IRS exceeded its authority.
- 4Company intends to file a petition with the U.S. Tax Court to contest the IRS assessment.
- 5BSX believes its tax filings are meritorious and tax reserves are adequate, expecting no material impact on financial condition.
- 6Resolution of the tax dispute is uncertain and could take several years, with potential for material impact if adverse.
- 7No payment is required until the dispute is definitively resolved.